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Mutations in PCYT1A, Encoding a Key Regulator of
Phosphatidylcholine Metabolism, Cause
Spondylometaphyseal Dysplasia with Cone-Rod Dystrophy
Julie Hoover-Fong,1,2,16,* Nara Sobreira,3,16 Julie Jurgens,3,4 Peggy Modaff,5 Carrie Blout,1 Ann Moser,6
Ok-Hwa Kim,7 Tae-Joon Cho,8 Sung Yoon Cho,9 Sang Jin Kim,10 Dong-Kyu Jin,11 Hiroshi Kitoh,12
Woong-Yang Park,13,14 Hua Ling,15 Kurt N. Hetrick,15 Kimberly F. Doheny,15 David Valle,2,3
and Richard M. Pauli5The spondylometaphyseal dysplasias (SMDs) are a group of
about a dozen rare disorders characterized by short stature,
irregular, flat vertebrae, and metaphyseal abnormalities.
Aside from spondylometaphyseal dysplasia Kozlowski
type (MIM 184252) caused by mutations in TRPV4 (MIM
605427) and spondyloenchondrodysplasia (MIM 607944)
resulting from mutations in ACP5 (MIM 171640), the ge-
netic etiologies of SMDs are unknown.1 Two of these unex-
plained SMDs have ophthalmologic manifestations: SMD
with cone-rod dystrophy (SMD-CRD [MIM 608940]) and
axial SMD with retinal degeneration (MIM 602271).
Delineated clinically a decade ago, SMD-CRD is a pre-
sumed autosomal-recessive disorder with postnatal growth
deficiency leading to profound short stature; rhizomelia
with bowing of the lower extremities; platyspondyly
with anterior vertebral protrusions; progressive metaphy-
seal irregularity and cupping with shortened tubular
bones; and early-onset, progressive visual impairment
associated with a pigmentary maculopathy and electro-
retinographic evidence of cone-rod dysfunction.2–5 In
contrast to retinitis pigmentosa, the CRDs have early
involvement of cone photoreceptors.6
Here, we report loss-of-function mutations in PCYT1A
(MIM 123695) as the cause of SMD-CRD. PYCT1A encodes
CTP:phosphocholine cytidylyltransferase (CCTa),7,8 a key
enzyme in the CDP-choline or Kennedy pathway for de
novo phosphatidylcholine biosynthesis.
We used whole-exome and targeted sequencing of
members of six unrelated families with eight individuals
with SMD-CRD (Figure 1). Three families were submitted
to the Baylor-Hopkins Center for Mendelian Genomics1McKusick-Nathans Institute of Genetic Medicine, Greenberg Center for Ske
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The Amer(BHCMG) through the online submission portal Phe-
noDB9 and, to confirm our observations in the first three
families, we recruited three additional families for targeted
candidate gene sequencing. Local approval for this study
was provided by the Johns Hopkins Institutional Review
Board, and all participants signed an informed consent.
The clinical features of these individuals are summarized
in Table 1 and briefly reviewed here. Six of the subjects
have been described in previous publications.2,5
Subject 1 (BH2265_1; family 1; Figure 2A) was reported
when she was 20 years old.2 Now age 29, she has done
well with continued linear growth to an adult height of
93.9 cm (10.7 SD) and modest progression of limitation
of range of motion. Visual impairment has not progressed
since around age 10. Subject 2 (BH2283_1; family 2,
Figure 2E), originally described at age 11 years, is now 20
years old with a current adult height of 139 cm (5.3
SD) and some progression of joint stiffening. His visual
function declined during his second decade and he now
requires low-vision aids. Subject 3 (BH2233_1; family 3)
is a previously unreported 61-year-old female who was first
seen at age 51. Although her skeletal phenotype is similar
to that of the others described here, she had a late-onset
retinal phenotype (Figure 2B). Radiographs from child-
hood were reported to show platyspondyly and metaphy-
seal changes; adult radiographs show hypoplasia of the
posterior vertebral bodies but no anterior vertebral protru-
sions. Adult height (measured at age 54) is 108.3 cm (8.4
SD). Visual symptoms were not apparent until middle age.
An ERG at age 43 (performed because she had a brother
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Figure 1. Pedigrees of Families 1–6
Showing the Segregation of PCYT1A
Mutant Alleles
Alleles with the wild-type genotype indi-
cated by plus sign. Samples were not avail-
able for individuals lacking a genotype
designation.51, however, her ERG showed evidence of cone-rod
dysfunction and her current vision is limited (Table 1).
At age 54, her examination showed short stature, rhizo-
melic limb shortening, brachydactyly, stiffness of large
joints, and internal tibial torsion. Her family history
includes an affected brother, who died at age 45 and was
known to have short stature and a confirmed CRD. Her
parents may be distantly related. Subjects 4–6 were
reported by Walters et al.2 as their cases 3–5 and have
not been formally assessed since that time but provided
updated information regarding visual function (Table 1,
Figures 2C and 2D). Subject 7 (family 5) was previously
described.5 Subject 8 (family 6) is a 23-month-old previ-
ously unreported Korean male referred for evaluation of
growth failure and disproportionate shortening of the
limbs. He has an increased antero-posterior thoracic diam-
eter, rhizomelic shortening of his extremities, bilateral
bowing of the legs, and mildly limited elbow extension,
knee extension, and hip abduction. No visual or hearing
impairment was noted at his first examination. Linear
growth was impaired (by North American standards): at
23 months he was 68.4 cm (5.2 SD) and at 48 months,
71.2 cm (7.4 SD). From age 2 years he had frequent pneu-
monias with episodes of desaturation and O2 dependency
thought to be due to chest wall deformity. He had a
waddling gait because of coxa vara deformity. Radiographs
at 23 months showed short, bowed long bones with
flared, cupped, and spurred metaphyses, and the adjacent
epiphyses were large and rounded. In the hands and feet,
the metaphyses of the short tubular bones had mild
cupping, widening, and flaring and the diaphyses were
short. The vertebral bodies were ovoid, mildly flattened,
with anterior projections. These radiographic abnormal-
ities were more severe at age 45 months. Mild scoliosis
developed. Although no visual impairment was noted at
age 23 months, by age 45 months fundus examination
showed hypopigmented macular atrophy in both eyes
with markedly decreased photopic and moderately
decreased scotopic ERGs.106 The American Journal of Human Genetics 94, 105–112, January 2, 2014For our molecular studies, we iso-
lated genomic DNA from fresh whole
blood via the Gentra Puregene Kit
(QIAGEN Sciences). Subjects 1, 2,
and 3 were genotyped on Illumina’s
ExomeChip1.1 GWAS array. This
allows us to estimate inbreeding co-
efficient based on the observed and
expected homozygous genotypes atgenome-wide level among 199 samples from unrelated
white individuals (defined by PCA) after LD pruning
(PLINK). The inbreeding coefficient was 0.1535, 0.007,
and 0.035 for subjects 1, 2, and 3, respectively, suggesting
that subject 1 (BH2265_1) is the product of an unrecog-
nized consanguineous union. Although subject 3 is also
homozygous for p.Ala99Val mutation, B allele frequency
plot showed multiple loss-of-heterozygosity segments
across genome for subject 1 but not subject 3. This result
suggests that homozygosity for p.Ala99Val in subject 1 is
a result of consanguinity whereas in subject 3 it is the result
of recurrent mutation (see below).
For WES, we captured the CCDS exonic regions and
flanking intronic regions totaling ~51 Mb by using the
Agilent SureSelect Human All Exon V4 51Mb Kit and
performed paired end 100 bp reads on subjects 1–3 with
the Illumina HiSeq2000 platform. We aligned each read
to the reference genome (NCBI human genome assem-
bly build 37; Ensembl core database release 50_36110)
with the Burrows-Wheeler Alignment (BWA) tool11 and
identified single-nucleotide variants (SNVs) and small
insertion-deletions (indels) with SAMtools.12 We also per-
formed local realignment and base call quality recalibra-
tion by using GATK.13,14 We identified potentially causal
variants by standard filtering criteria: SNV and indel mini-
mal depth of 83, root mean square mapping quality of 25,
strand bias p value below 104, end distance bias below
104, and filtering out SNVs within 3 bp of an indel and in-
dels within 10 bp of each other; followed by the use of the
Analysis Tool of PhenoDB9 to design the prioritization
strategy (N.S., unpublished data). We prioritized rare func-
tional variants (missense, nonsense, splice site variants,
and indels) that were homozygous or compound heterozy-
gous in each of the three subjects and excluded variants
with a MAF > 0.01 in dbSNP 126, 129, and 131 or in the
Exome Variant Server (release ESP6500SI-V2) or 1000
Genomes Project.15 We also excluded all variants found
in our in-house controls (CIDRVar 51Mb). We generated
a homozygous and a compound heterozygous variant list
Table 1. Demographic, Clinical, and Molecular Findings
Family 1 Family 2 Family 3 Family 4 Family 5 Family 6
Subject 1
(BH2265_1)
Subject 2
(BH2283_1)
Subject 3
(BH2233_1) Subject 4 Subject 5 Subject 6 Subject 7 Subject 8
Previously reported Walters et al.2
(case 1)
Walters et al.2
(case 2)
no Walters et al.2
(case 3)
Walters et al.2
(case 4)
Walters et al.2
(case 5)
Kitoh et al.5 no
Family origin North Europe North Europe Greece North Europe North Europe North Europe Japan Korea
Age of initial
recognition
7 months 13 months 51 years 36 months 27 months 24 months 6 months 23 months
Best corrected visual
acuity
20/100 20/180 8/80 5/250 20/250 10/250 NA NA
Pigmentary
maculopathy
þ þ þ þ þ þ þ þ
Cone-rod dystrophy
(age of diagnosis)
þ (13.5 years) þ (17 months) þ (51 years) þ (36 months) þ (27 months) ND þ (11 years) þ
Height SD (most
recent measurement
available)
10.7 SD 5.3 SD 8 0.4 SD NA 6.1 SD NA 7.9 SD 7.4 SD
Bowing of long
bones
þ þ þ þ þ þ þ þ
Platyspondyly þ þ þ þ þ þ þ þ
Metaphyseal
irregularity and
cupping
þ þ þ þ þ þ þ þ
PCTY1A genotype c.296C>T,
c.296C>T
c.296C>T,
c.448C>G
c.296C>T,
c.296C>T
c.847C>T,
c.295G>A
c.847C>T,
c.295G>A
c.847C>T,
c.295G>A
c.990delC,
c.669G>C
c.385G>A,
c.571T>C
PCTY1A protein
change
p.Ala99Val,
p.Ala99Val
p.Ala99Val,
p.Pro150Ala
p.Ala99Val,
p.Ala99Val
p.Arg283*,
p.Ala99Thr
p.Arg283*,
p.Ala99Thr
p.Arg283*,
p.Ala99Thr
p.Ser331Profs*?,
p.Arg223Ser
p.Glu129Lys,
p.Phe191Leu
SIFT 0.04 0.04, 0 0.04 0, 0.04 0, 0.04 0, 0.04 NA, 0 0.02, 0
PolyPhen 1 1, 1 1 1, 1 1, 1 1, 1 NA, 0.791 1, 1for each subject and merged them to identify genes that
were mutated in both alleles in all three subjects. We de-
signed PCR primers to amplify exons and flanking intronic
splice sites followed by direct Sanger sequencing to vali-
date candidate causative variants, determine their segrega-
tion within families, and sequence PCYT1A in subjects
4–8. All the variants described here were based on the
RefSeq transcript NM_005017.2 and NCBI human genome
assembly build 37 (Table 1).
Analysis ofWES data in subjects 1–3 identified two genes
containing candidate causal mutations in all three sub-
jects: TTN (MIM 188840) and PCYT1A. TTN is a large
gene (313 exons) expressed primarily in skeletal and car-
diac muscle.16 TTN variants are found frequently in con-
trols17 and have been implicated as causative in various
cardiac and skeletal myopathies,17–24 but not in individ-
uals with retinal or skeletal dysplasia phenotypes. For these
reasons, we removed TTN from consideration, leaving
PCYT1A as the only gene with rare variants in both alleles
in all three subjects. Subjects 1 and 3 are homozygous for
the PCYT1A missense variant p.Ala99Val (c.296C>T) in
exon 5 and subject 2 is a compound heterozygote for
p.Ala99Val and p.Pro150Ala (c.448C>G) in exon 6 of
PCYT1A. These variants are not present in the>6,000 indi-The Amerviduals in the Exome Variant Server nor in the 1,092 indi-
viduals whose sequence is currently available from the
1000 Genomes. Direct Sanger sequencing of PCR-ampli-
fied products confirmed appropriate Mendelian segre-
gation of these variants in available family members
(Figure 1). Based on these results, we used PCR and bidirec-
tional Sanger sequencing to interrogate all PCYT1A exons
and flanking intronic sequence in subjects 4–8 (three pro-
bands and two affected sibs). All were compound heterozy-
gotes for rare PCYT1A variants.
Thus, in total, we identified eight rare PCYT1A variants
(one nonsense, one frame-shifting indel, and six missense
variants) present either in the homozygous or compound
heterozygous state in eight individuals with SMD-CRD in
six families from around the world (Table 1). The missense
mutations all change highly conserved residues, including
one, Ala99, that is altered by two different variants
(p.Ala99Val and p.Ala99Thr) and all are predicted to be
damaging by SIFT25 and either probably damaging or
possibly damaging by PolyPhen-2 (Table 1).26 The
c.296C>T variant producing the p.Ala99Val change occurs
at a CpG dinucleotide on the reverse strand, whereas the
mutation in the same codon producing p.Ala99Thr
(c.295G>A) in family 4 does not involve a CpGican Journal of Human Genetics 94, 105–112, January 2, 2014 107
Figure 2. Clinical and Radiographic Features of SMD-CRD
(A) General physical phenotype (subject 1 at age 16 years
5 months).
(B) Fundus photograph showing pigmentary maculopathy (sub-
ject 3 at age 61 years).
(C) Spine and pelvis radiograph demonstrating platyspondyly,
characteristic pelvic configuration, and proximal femoral meta-
physeal changes (subject 6 at 3 years 8 months).
(D) Pelvis and femurs showing the marked metaphyseal changes
that are typical (subject 4 at age 11 years 1 month).
(E) Knee radiographs, similarly showing the marked metaphyseal
changes that are typical in this diagnosis (subject 2 at 13 years).dinucleotide. To determine whether the three unrelated
subjects with the p.Ala99Val change have a shared or
recurrent mutation, we utilized the SNP genotyping data
to analyze IBD sharing and runs of homozygosity to
show that, as predicted by the different geographical
origins of the three families, the p.Ala99Val variants in
families 1–3 are on different haplotypes, indicating that
recurrent CpG mutations are responsible.
Located at 3q29, PCYT1A (Figure 3) contains 10 exons, is
ubiquitously expressed, andencodesCCTa, anamphitropic
enzyme that catalyzes the synthesis of CDP-choline from
phosphocholine and CTP. The CCTa reaction is the rate-
limiting step in themajorpathway forphosphatidylcholine
synthesis (Figure 4).7,8 In mammals, phosphatidylcholine
can also be synthesized from phosphatidylethanolamine
in a reaction catalyzed by phosphatidylethanolamine
N-methyltransferase (PEMT) but the expression of the
enzyme is limited to liver (Figure 4).7,8,27 Phosphatidylcho-
line is the predominant phospholipid in eukaryotic
membranes.7,8 Consistent with the importance of CCTa
in phosphatidylcholine synthesis, a mouse knockout of
Pcyt1a is early embryonic lethal in the homozygous
state.28 An X-linked PCYT1A paralog, PCYT1B (MIM
604926), encodes three isoforms (CCTb1, CCTb2, and
CCTb3) with activities similar to CCTa but whose expres-
sion is limited to the central nervous system.8,29
The 367 residue CCTa has 4 domains: a 73 residue N-ter-
minal domain containing the nuclear localizing signal,
a 163 residue catalytic domain, a 64 residue membrane-108 The American Journal of Human Genetics 94, 105–112, January 2binding M domain, and a C-terminal 67 residue unordered
domain with multiple residues that undergo phosphoryla-
tion (Figure 3).30,31 CCTa is found as an inactive homo-
dimer in the nucleoplasm where, in response to lipid
signaling, it binds to the nuclear membrane through inter-
actions mediated by the amphipathic M domain and
becomes catalytically active.8,30 The sequence and domain
structure of CCTa is highly conserved across phylogeny
and the crystal structure of the catalytic domain of rat
CCTa, which has 100% sequence identity with human
CCTa, has been solved.30
The PCYT1A missense alleles identified in the subjects
with SMD-CRD all involve residues conserved across verte-
brate and most of invertebrate and prokaryotic phylogeny.
All mutations change residues in the catalytic domain
of CCTa: Ala99 (altered in subjects 1–6) is adjacent to
Gln98, which is directly involved in binding CDP;
Pro150 (altered in proband 2) is adjacent to Trp151, which
is also directly involved in binding choline; and Phe191
(altered in proband 8) is located three residues N-terminal
to Thr194, which plays a role in coordinating CDP.
The p.Glu129Lys and p.Arg223Ser substitutions alter
residues that are linearly more distant from those that
interact directly with substrates.30 The nonsensemutation,
c.847C>T, occurs in the penultimate exon 9, 50 bp from
the 30 end of the exon, and possibly results in nonsense-
mediated RNA decay of the mutant transcript. The 1 bp
indel allele in subject 7 (c.990delC) changes the frame in
sequence encoded by the last exon in a way that predicts
continued translation all the way 30 to the site of poly(A)
addition. Such mutations have been termed ‘‘nonstop’’
alleles and are associated with dramatic reduction in
mRNA abundance.32 We conclude that these variants, on
the basis of the their extremely low frequency, the high
conservation of the involved residues and predicted
deleterious consequences for enzymatic activity, their
occurrence in homozygosity or compound heterozygosity
in multiple unrelated affected individuals in six families,
and their segregation fitting an autosomal-recessivemodel,
are PCYT1A loss-of-function alleles responsible for the
SMD-CRD phenotype.
Like the deficiency of choline kinase B caused by muta-
tions in CHKB (MIM 612395) responsible for muscular
dystrophy, congenital megaconial type (MIM 602541),33
SMD-CRD is the second inborn error in the phosphatidyl-
choline synthetic pathway described. The central impor-
tance of this lipid in membrane biology suggests that
complete loss of function of this pathway would result in
embryonic lethality, as observed in mice homozygous for
Pcyt1a-null alleles.28 Thus, it is puzzling that individuals
with SMD-CRD are healthy aside from their skeletal and
retinal involvement. One possible explanation is that
despite the predicted severe functional consequences of
the mutations we describe, there remains some residual
CCTa function. This may be augmented by activity of
the CCTb isozymes and by synthesis of phosphatidyl-
choline from phosphatidylethanolamine by the PEMT, 2014
Figure 3. PCYT1A Structure and Domain
Organization of CCTa
PCYT1A is located at 3q29 and includes
ten exons (gray rectangles) as shown on
the top line of the diagram. The thin rect-
angles encode the 50 and 30 UTR sequences.
The right angle arrow denotes the start of
the open reading frame and the asterisk
indicates the location of the stop codon.
The genomic coordinates on chromosome
3 are shown above. Below in color is a
diagram of CCTa showing the domain
structure with the diagonal dashed lines
indicating the exons that contribute to
each domain. The N-terminal domain (N)
is in light blue with a dark blue rectangle
indicating the position of the nuclear
localization signal. The catalytic domain
(C) is in pink. The amphitrophic membrane-binding domain (M) is in green and the C-terminal phosphorylated domain (P) is in purple.
The numbers below indicate the residues at the boundaries of the domains. The mutations and their locations are shown below.catalyzed reaction in the liver.8 The activities of the CCTb
isozymes and PEMT were increased in cells derived from
conditional Pcyt1a knockout mice.34,35 These possibilities
should be explored because they may suggest therapeutic
strategies that could be effective, especially in younger
SMD-CRD-affected individuals.
Our results suggest a connection between bone and
retinal lipid metabolism that would explain the sensitivity
of these two tissues to deficiency of CCTa and impaired
phosphatidylcholine synthesis. Photoreceptors have an
especially high demand on membrane biosynthesis
because of the daily shedding of outer segment discs.36
Therefore, it is not surprising that these cells might
be especially susceptible to defects in the biosynthetic
pathway for the most abundant membrane phospho-
lipid. Indeed, photoreceptor degeneration in the rd11
mouse has been shown to be due to loss-of-function mu-
tations in the gene encoding lysophosphatidylcholine
acyltransferase 1 (Lpcat1), a phospholipid remodeling
enzyme.37,38 Interestingly, bone formation is abnormal
in certain Mendelian disorders caused by mutations in
genes encoding proteins involved in fatty acid meta-
bolism, including rhizomelic chondrodysplasia punctata
(MIM 215100)39 and the Conradi-Hunermann form of
chondrodysplasia punctata (MIM 302960).40 These obser-
vations suggest key functions for membrane lipids in bone
formation and homeostasis.
In our study, there was no obvious genotype-phenotype
correlation apparent from evaluation of the six affected in-
dividuals in four families with mutations altering codon
Ala99. Subjects 1 and 3, both homozygous for c.296C>T
(p.Ala99Val), have strikingly dissimilar age at onset of
visual phenotype, of clinical characteristics, and of radio-
logic features. This broad range of phenotypic severity in
individuals with the same mutations at the disease gene
locus suggests that variation in other components of the
phosphatidylcholine pathways and/or environmental var-
iables may have a strong influence on phenotypic mani-
festations and severity. Understanding these variables
may lead to improved management of individuals withThe AmerSMD-CRD. Interestingly, one of the individuals described
here, subject 8, has had frequent pneumonias and has
required supplemental oxygen from age 2. We speculate
that this might relate to the high demand for phosphati-
dylcholine in surfactant biosynthesis by the alveolar type
II cells.41,42 These cells are known to express PCYT1A at
high levels and phosphatidylcholine is the major phos-
pholipid component of surfactant.41–43 A conditional,
epithelial cell-specific Pcyt1a knockout mouse had severe
respiratory failure at birth and reduced levels of surfac-
tant.44 Although only one of the individuals described
here has had this problem, the potential biological con-
nections suggest that additional studies of pulmonary
function and surfactant status in proband 8 and possibly
other cases of SMD-CRD is warranted.
To our knowledge, SMD-CRD is the only described disor-
der in which CRD is associated with a skeletal dysplasia. By
contrast, there are several examples of RP associated with
bony abnormalities including some for which the respon-
sible gene is yet to be identified.45,46 CRD and RP may be
part of the same phenotypic spectrum of retinal degenera-
tion. Mutations in certain genes have been reported to
cause either phenotype.47,48 For this reason, we suggest
that PCYT1A should be assessed in any individual with
CRD or RP associated with any form of spondylometaphy-
seal dysplasia or spondyloepiphyseal dysplasia, including
in particular individuals with axial SMD with retinal
degeneration phenotype (MIM 602271).Supplemental Data
Supplemental Data include one figure and can be found with this
article online at http://www.cell.com/AJHG/.Acknowledgments
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Figure 4. Pathways of Phosphatidylcho-
line Biosynthesis
Enzymes are indicated by numbers as
defined below. Choline (Cho) is trans-
ported from the extracellular fluid across
the plasma membrane by Naþ-dependent,
ATP-requiring choline transporter-like
proteins (1). Free intracellular choline is
phosphorylated by choline kinase (2) to
produce phosphocholine (P-Cho). The
latter is converted to cytidine-diphosphate
choline (CDP-Cho) in a reaction catalyzed
by phosphocholine cytidylyltransferase
(CCTa, 3). CDP-choline is esterified with
diacylglycerol (DAG) to phosphatidylcho-
line (PtdCho) in reactions catalyzed either
by cholinephosphotransferase (4) or choline/ethanolaminephosphotransferase (5). PtdCho is converted to lyso-phosphatidylcholine
(Lyso-PtdCho) by phospholipase A (6) which, in turn, is converted back to PtdCho, in a reaction catalyzed by acylglycerophosphate
acyltransferase (7). In mammals, a second pathway of PtdCho synthesis is limited to liver, where PtdCho is synthesized from phospha-
tidylethanolamine (Ptd-Eth) in a series of methylation reactions catalyzed by phosphatidylethanolamine N-methyltransferase (8) with
S-adenosylmethionine (SAM) as the methyl donor. The red rectangle indicates the position of the block in PtdCho synthesis caused by
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